Publications by authors named "Kent Shih"

Claim this Profile
P
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma.
Anna F Piotrowski, Kent Shih, Pierre Giglio, Howard Colman, Patrick Y Wen

Curr Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot survey into the landscape of neuro-oncology care in the community.
Christine Lu-Emerson, Sajeel Chowdhary, Rupesh Kotecha, Akanksha Sharma, Yazmin Odia, Kent Shih

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma.
Gerald S Falchook, James D Battiste, Amandeep Kalra, Mythili Shastry, Lindsey Finney, Meredith G Shih, Kent C Shih

Neurooncol Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Kent C Shih

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
David R Spigel, Dianna L Shipley, David M Waterhouse, Suzanne F Jones, Patrick J Ward, Kent C Shih

Oncologist· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
John D Hainsworth, Kevin P Becker, Tarek Mekhail, Sajeel A Chowdhary, Janice Faulkner Eakle, Kent Shih

J Neurooncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib Prior to Selective Internal Radiation Therapy Using Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers.
Andrew Kennedy, Dianna Shipley, Max Shpak, Laura Blakely, Brian Hemphill, Kent Shih

Front Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
Sandra P D'Angelo, Matthias Hunger, Andrew S Brohl, Paul Nghiem, Shailender Bhatia, Kent C Shih

Cancer Immunol Immunother· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
Johann S de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Kent C Shih

Clin Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Drew W Rasco, Kyriakos P Papadopoulos, Michael Pourdehnad, Anita K Gandhi, Patrick R Hagner, Kent Shih

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Rimas V Lukas, Jordi Rodon, Kevin Becker, Eric T Wong, Kent Shih

J Neurooncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
David R Spigel, Howard A Burris, F Anthony Greco, Kent C Shih, Victor G Gian

Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
John D Hainsworth, David M Waterhouse, Kent C Shih, Ralph V Boccia, Victor M Priego

Lung Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Howard L Kaufman, Jeffery S Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Kent C Shih

J Immunother Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
David R Spigel, Mark S Rubin, Victor G Gian, Dianna L Shipley, Howard A Burris, Kent C Shih

Lung Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Kent C Shih

Lancet Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard

J Neurooncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
Johanna C Bendell, Ahmed Zakari, Evan Lang, David Waterhouse, Douglas Flora, Kent Shih

Cancer Invest· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Johanna C Bendell, Robin K Kelley, Kent C Shih, Jennifer A Grabowsky, Emily Bergsland

Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Johanna C Bendell, Carla Kurkjian, Jeffrey R Infante, Todd M Bauer, Howard A Burris, Kent C Shih

Invest New Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of checkpoint inhibitors as novel cancer therapies.
Kent Shih, Hendrik-Tobias Arkenau, Jeffrey R Infante

Drugs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.
Kent C Shih, Mythili Shastry, Jeffrey T Williams, Peter F Jelsma, Steven R Abram

J Clin Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Ralph J Hauke, Jeffrey R Infante, Mark S Rubin, Kent C Shih, Edward R Arrowsmith

Melanoma Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
John D Hainsworth, Kent C Shih, Gregg C Shepard, Guy W Tillinghast, Brett T Brinker

Clin Adv Hematol Oncol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis